<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507738</url>
  </required_header>
  <id_info>
    <org_study_id>MT-5625-01</org_study_id>
    <nct_id>NCT03507738</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study to Assess the Safety and Immunogenicity of an Investigational Non-Replicating Rotavirus Vaccine (MT-5625) in Healthy Adults, Toddlers and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the safety and reactogenicity of MT-5625 independently in adults aged
      18-35 years, toddlers ages 12-24 months, and infants aged 6-10 weeks
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with local reactions and reactogenicity events.</measure>
    <time_frame>Within 7 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects reporting adverse events.</measure>
    <time_frame>Within 28 days after each vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with anti-MT-5625 IgG seroresponses</measure>
    <time_frame>Day 28 after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with neutralizing antibody responses</measure>
    <time_frame>Day 28 after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-MT-5625 IgG geometric mean titers (GMTs) 28 days after each injection in adults, toddlers, and infants.</measure>
    <time_frame>Day 28 after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody GMTs against rotavirus 28 days after each injection in adults, toddlers and infants.</measure>
    <time_frame>Day 28 after each vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Adult MT-5625 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult MT-5625 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult receiving intramuscular injection with either high dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler MT-5625 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddler MT-5625 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant MT-5625 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant receiving intramuscular injection with either low dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant MT-5625 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant MT-5625 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant receiving intramuscular injection with either high dose of MT-5625 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotarix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant receiving oral administration with Rotarix</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MT-5625 low dose</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Infant MT-5625 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MT-5625 middle dose</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Adult MT-5625 middle dose</arm_group_label>
    <arm_group_label>Toddler MT-5625 middle dose</arm_group_label>
    <arm_group_label>Infant MT-5625 middle dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MT-5625 high dose</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Adult MT-5625 high dose</arm_group_label>
    <arm_group_label>Toddler MT-5625 high dose</arm_group_label>
    <arm_group_label>Infant MT-5625 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Rotarix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Adult MT-5625 middle dose</arm_group_label>
    <arm_group_label>Adult MT-5625 high dose</arm_group_label>
    <arm_group_label>Toddler MT-5625 middle dose</arm_group_label>
    <arm_group_label>Toddler MT-5625 high dose</arm_group_label>
    <arm_group_label>Infant MT-5625 low dose</arm_group_label>
    <arm_group_label>Infant MT-5625 middle dose</arm_group_label>
    <arm_group_label>Infant MT-5625 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female adults/toddlers/infants as established by medical history and
             clinical examination before entering the study

          -  Adults aged &gt;18 and &lt; 35, toddlers aged &gt;12 and &lt; 24 months, and infants aged &gt; 6 and
             &lt; 10 weeks at the time of enrollment

          -  Subject (or Parent/Legal Guardian) willing and able to give written informed consent
             after the nature of the study has been explained

          -  Subject (or Parent/Legal Guardian) willing to comply with the study restrictions and
             study schedule and to remain in the area for the study duration

          -  Females of potential childbearing must not be pregnant or breastfeeding and willing to
             use adequate method of contraception during the trial

        Exclusion Criteria:

        ALL SUBJECTS

          -  Presence of fever or other acute illness

          -  Concurrent participation in another clinical trial or receipt of an investigational
             product during the 30 days prior to randomization

          -  Suspected or known impairment of immune function

          -  Known sensitivity to any components of the study vaccine

          -  History of anaphylactic reaction

          -  Receipt of immunoglobulin therapy or blood products in last 6 months

          -  History of chronic immunosuppressive medications (with the exception of inhaled or
             topical steroids)

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the volunteer at risk because of participation in the
             study, or influence the results or the volunteer's ability to participate in the study

        ADULTS ONLY

          -  Have received any vaccine within 4 weeks prior to randomization

          -  Any clinically significant illness, medical/surgical procedure, or trauma within 4
             weeks of the first administration of investigational product (IP)

          -  Any clinically significant abnormalities on 12-lead ECG as judged by the Investigator

          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis C
             antibody, and human immunodeficiency virus (HIV) antibody

          -  Have any contraindications to parenteral injections ( eg history of bleeding disorder)

          -  Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as
             judged by the Investigator

          -  Donated blood within the 4 weeks prior to randomization

        TODDLERS and INFANTS

          -  Received any vaccine within 14 days of randomization

          -  Presence of malnutrition or other systemic disorders

          -  History of congenital abdominal disorders, intussusception or abdominal surgery

          -  Major congenital or genetic defect

        TODDLERS ONLY

          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis B
             core antibody, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

        INFANTS ONLY

          -  Infants with history of premature birth (&lt;37 weeks gestational age)

          -  Infants who have received rotavirus vaccine in the past

          -  Known sensitivity to any components of the study vaccine, including Rotarix®

          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis B
             core antibody, and hepatitis C antibody

          -  HIV infection assessed by PCR if mother is not known to be negative (negative test
             result between 24 weeks gestation and screening).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk, to prevent miscommunication,</last_name>
    <phone>please email:</phone>
    <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

